Biotechnology
Compare Stocks
2 / 10Stock Comparison
ASBPW vs ACB
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
ASBPW vs ACB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $125K | $195M |
| Revenue (TTM) | $2K | $361M |
| Net Income (TTM) | $-32M | $41M |
| Gross Margin | 45.5% | 62.7% |
| Operating Margin | -10314.0% | 13.3% |
| Forward P/E | — | 164.2x |
| Total Debt | $1M | $104M |
| Cash & Equiv. | $4K | $184M |
ASBPW vs ACB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBPW) | 100 | 25.3 | -74.7% |
| Aurora Cannabis Inc. (ACB) | 100 | 67.3 | -32.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBPW vs ACB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ASBPW is the clearest fit if your priority is long-term compounding.
- -81.9% 10Y total return vs ACB's -92.0%
ACB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.81
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- Lower volatility, beta 1.81, Low D/E 17.2%, current ratio 4.31x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.0% revenue growth vs ASBPW's -25.4% | |
| Quality / Margins | 11.2% margin vs ASBPW's -16K% | |
| Stability / Safety | Beta 1.81 vs ASBPW's 3.15 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -25.3% vs ASBPW's -66.2% | |
| Efficiency (ROA) | 5.2% ROA vs ASBPW's -13.2% |
ASBPW vs ACB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ACB leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACB is the larger business by revenue, generating $361M annually — 186051.0x ASBPW's $1,941. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to ASBPW's -16351.8%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $361M |
| EBITDAEarnings before interest/tax | -$28M | $71M |
| Net IncomeAfter-tax profit | -$32M | $41M |
| Free Cash FlowCash after capex | -$4M | -$31M |
| Gross MarginGross profit ÷ Revenue | +45.5% | +62.7% |
| Operating MarginEBIT ÷ Revenue | -10314.0% | +13.3% |
| Net MarginNet income ÷ Revenue | -16351.8% | +11.2% |
| FCF MarginFCF ÷ Revenue | -1811.5% | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.0% | -94.5% |
Valuation Metrics
ASBPW leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $125,312 | $195M |
| Enterprise ValueMkt cap + debt − cash | $1M | $136M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | 164.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.73x |
| Price / SalesMarket cap ÷ Revenue | — | 0.77x |
| Price / BookPrice ÷ Book value/share | — | 0.43x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ACB leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs ASBPW's 3/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | +7.2% |
| ROA (TTM)Return on assets | -13.2% | +5.2% |
| ROICReturn on invested capital | — | +0.7% |
| ROCEReturn on capital employed | — | +0.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | — | 0.17x |
| Net DebtTotal debt minus cash | $1M | -$80M |
| Cash & Equiv.Liquid assets | $3,633 | $184M |
| Total DebtShort + long-term debt | $1M | $104M |
| Interest CoverageEBIT ÷ Interest expense | -10.51x | 6.27x |
Total Returns (Dividends Reinvested)
Evenly matched — ASBPW and ACB each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ASBPW five years ago would be worth $1,810 today (with dividends reinvested), compared to $385 for ACB. Over the past 12 months, ACB leads with a -25.3% total return vs ASBPW's -66.2%. The 3-year compound annual growth rate (CAGR) favors ACB at -19.2% vs ASBPW's -43.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -18.3% | -21.0% |
| 1-Year ReturnPast 12 months | -66.2% | -25.3% |
| 3-Year ReturnCumulative with dividends | -81.9% | -47.2% |
| 5-Year ReturnCumulative with dividends | -81.9% | -96.1% |
| 10-Year ReturnCumulative with dividends | -81.9% | -92.0% |
| CAGR (3Y)Annualised 3-year return | -43.4% | -19.2% |
Risk & Volatility
ACB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACB is the less volatile stock with a 1.81 beta — it tends to amplify market swings less than ASBPW's 3.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 51.4% from its 52-week high vs ASBPW's 16.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.15x | 1.81x |
| 52-Week HighHighest price in past year | $0.09 | $6.67 |
| 52-Week LowLowest price in past year | $0.01 | $3.07 |
| % of 52W HighCurrent price vs 52-week peak | +16.9% | +51.4% |
| RSI (14)Momentum oscillator 0–100 | 52.4 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 23K | 979K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $5.92 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ACB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ASBPW leads in 1 (Valuation Metrics). 1 tied.
ASBPW vs ACB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ASBPW or ACB a better buy right now?
Aurora Cannabis Inc.
(ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Aurora Cannabis Inc. (ACB) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBPW or ACB?
Over the past 5 years, Aspire Biopharma Holdings, Inc.
(ASBPW) delivered a total return of -81. 9%, compared to -96. 1% for Aurora Cannabis Inc. (ACB). Over 10 years, the gap is even starker: ASBPW returned -81. 9% versus ACB's -92. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBPW or ACB?
By beta (market sensitivity over 5 years), Aurora Cannabis Inc.
(ACB) is the lower-risk stock at 1. 81β versus Aspire Biopharma Holdings, Inc. 's 3. 15β — meaning ASBPW is approximately 74% more volatile than ACB relative to the S&P 500.
04Which is growing faster — ASBPW or ACB?
On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc.
grew EPS 102. 2% year-over-year, compared to -381. 5% for Aspire Biopharma Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ASBPW or ACB?
Aurora Cannabis Inc.
(ACB) is the more profitable company, earning 0. 5% net margin versus -16351. 8% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -10314. 0% for ASBPW. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ASBPW or ACB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ASBPW or ACB better for a retirement portfolio?
For long-horizon retirement investors, Aurora Cannabis Inc.
(ACB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Aspire Biopharma Holdings, Inc. (ASBPW) carries a higher beta of 3. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACB: -92. 0%, ASBPW: -81. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ASBPW and ACB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ASBPW is a small-cap quality compounder stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.